An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene - PubMed

Affiliations

• PMID: 7534797

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene

R E Toes et al. J Immunol. 1995.

Abstract

Mouse embryo cells (C57BL/6, H-2b) transformed by the E1A and E1B genes of adenovirus type 5 (Ad5E1 MEC) are highly immunogenic. Previously, CTL were cloned from mice immunized with Ad5E1 MEC. These CTL clones were capable of tumor eradication in nude mice, and were directed against the Ad5E1A-encoded decapeptide SGPSNTPPEI, presented by the H-2Db MHC molecule. We have now generated Ad5E1 MEC containing a mutated Ad5E1A-encoded epitope. The mutant Ad5E1 MEC induce a strong CTL response when injected into immunocompetent mice. CTL clones generated against mutant Ad5E1-transformed tumor cells recognize an Ad5E1B-encoded epitope (VNIRNCCYI) in the context of H-2Db. Because this epitope is also present on wild-type Ad5E1 MEC, it is concluded that Ad5E1-transformed tumor cells express at least two CTL epitopes. Interestingly, the lysis of Ad5E1 MEC by the Ad5E1B-specific, but not by the Ad5E1A-specific, CTL clones was strongly diminished by the action of the activated ras oncogene. CTL directed against the Ad5E1B-encoded epitope were, like Ad5E1A-specific CTL, able to eradicate large established Ad5E1-induced tumors in B6 nude mice, demonstrating that CTL activity directed against different CTL epitopes expressed by the same tumor can be exploited for immunotherapy of cancer.

Similar articles

• Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.

  Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Cancer Res. 1996 Aug 15;56(16):3782-7. Cancer Res. 1996. PMID: 8706024

• Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.

  Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Abrams SI, et al. Eur J Immunol. 1996 Feb;26(2):435-43. doi: 10.1002/eji.1830260225. Eur J Immunol. 1996. PMID: 8617315

• Efficacy of cytotoxic T lymphocytes against virus-induced tumors.

  Melief CJ, Kast WM. Melief CJ, et al. Cancer Cells. 1990 Apr;2(4):116-20. Cancer Cells. 1990. PMID: 2143919 Review.

• Transforming collaborations between ras and nuclear oncogenes.

  Ruley HE. Ruley HE. Cancer Cells. 1990 Aug-Sep;2(8-9):258-68. Cancer Cells. 1990. PMID: 2223387 Review.

Cited by

• Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

  Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ. Vierboom MP, et al. J Exp Med. 1997 Aug 29;186(5):695-704. doi: 10.1084/jem.186.5.695. J Exp Med. 1997. PMID: 9271585 Free PMC article.

• CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

  Dace DS, Chen PW, Niederkorn JY. Dace DS, et al. Immunology. 2008 Mar;123(3):367-77. doi: 10.1111/j.1365-2567.2007.02700.x. Epub 2007 Oct 17. Immunology. 2008. PMID: 17944931 Free PMC article.

• Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.

  Singh-Jasuja H, Toes RE, Spee P, Münz C, Hilf N, Schoenberger SP, Ricciardi-Castagnoli P, Neefjes J, Rammensee HG, Arnold-Schild D, Schild H. Singh-Jasuja H, et al. J Exp Med. 2000 Jun 5;191(11):1965-74. doi: 10.1084/jem.191.11.1965. J Exp Med. 2000. PMID: 10839811 Free PMC article.

• IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.

  Coursey TG, Chen PW, Niederkorn JY. Coursey TG, et al. J Immunol. 2011 Oct 15;187(8):4219-28. doi: 10.4049/jimmunol.1100826. Epub 2011 Sep 14. J Immunol. 2011. PMID: 21918192 Free PMC article.

• Decreased tumor surveillance in perforin-deficient mice.

  van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. van den Broek ME, et al. J Exp Med. 1996 Nov 1;184(5):1781-90. doi: 10.1084/jem.184.5.1781. J Exp Med. 1996. PMID: 8920866 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Immune Epitope Database and Analysis Resource

• Research Materials

  • NCI CPTC Antibody Characterization Program